SK Biopharmaceuticals Co., Ltd.
326030
Peringkat dalam Saham
#3730
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Harga Saham
$56.51
Kapitalisasi Pasar
$4.43B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-25.24%
Negara
KR
Perdagangan SK Biopharmaceuticals Co., Ltd. (326030)
Kategori
Healthcare
Riwayat harga saham SK Biopharmaceuticals Co., Ltd. (326030)
Harga penutupan tertinggi: $51.70 pada 2026-10-01
Harga penutupan terendah: $157.85 pada 2020-07-01
Harga penutupan terendah: $157.85 pada 2020-07-01
Riwayat harga saham SK Biopharmaceuticals Co., Ltd. dari 2020 hingga 2026
Performa harga saham tahunan
| Tahun | Performa |
|---|---|
| 2026 (TTM) | -22.47% |
| 2025 | 24.61% |
| 2024 | 2.56% |
| 2023 | 25.24% |
| 2022 | -33.05% |
| 2021 | -47.19% |
| 2020 | 0.00% |
Harga saham perusahaan atau pesaing serupa
| Perusahaan | Harga saham | Perubahan 1th% | Negara |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
